序贯 TIL 输注靶向胰腺癌瘤内异质性

Targeting intratumoral heterogeneity in pancreatic cancer with sequential TIL infusions.

αPD-1 偶联的酸可裂解纳米药物克服胰腺肿瘤中的细胞免疫治疗障碍

αPD-1-conjugated acid-cleavable nanodrugs overcomes cellular immunotherapy barriers in pancreatic tumors.

胰腺导管腺癌肿瘤免疫微环境再审视——探索“空间”

Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited - Exploring the "Space".

基于集成微流控的抗 BTN2A2 凝胶微滴细胞制剂构建用于非侵入性 TIL（肿瘤浸润淋巴细胞）治疗

Integrated microfluidics-based construction of anti-BTN2A2 gel droplet cell preparations for non-invasive tumor-infiltrating lymphocyte therapy.

基于流式细胞术的胰腺癌小鼠模型中 TIL（肿瘤浸润淋巴细胞）的分离及治疗评估

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer.

编码 4-1BBL 和 IL15 的溶瘤病毒增强肝细胞癌中 TIL（肿瘤浸润淋巴细胞）过继治疗的疗效

Oncolytic virus encoding 4-1BBL and IL15 enhances the efficacy of tumor-infiltrating lymphocyte adoptive therapy in HCC.

自体 TIL（肿瘤浸润淋巴细胞）在复发/难治性卵巢癌、结直肠癌和胰腺导管腺癌中的疗效与安全性

Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal a

在 4-1BB 和 CD3 激动作用的辅助下制备的 TIL 是可行的，且治疗未伴随新的安全性信号。

以自体 T 细胞作为抗原呈递细胞从人胰腺肿瘤中扩增 KRAS 热点突变反应性 T 细胞

Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells.

胰腺癌患者来源异种移植模型的遗传学与 TIL（肿瘤浸润淋巴细胞）治疗应答

Genetics and Therapeutic Responses to Tumor-Infiltrating Lymphocyte Therapy of Pancreatic Cancer Patient-Derived Xenograft Models.

胰腺癌 PDX 模型可用于深入了解肿瘤特征和生物标志物，并评估过继性细胞疗法和联合疗法的反应。该模型的主要优势在于，可以在自体人源化小鼠模型中测试 T 细胞的修饰，从而获得支持启动临床试验的临床前数据。